Department of Pain Management, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Pain Med. 2010 May;11(5):685-91. doi: 10.1111/j.1526-4637.2010.00806.x. Epub 2010 Mar 4.
BACKGROUND, OBJECTIVES, AND METHODS: A few recent reports suggested that spinal cord stimulation (SCS) effectively suppresses chronic abdominal pain. However, there is no consensus on patient selection or technical aspects of SCS for such pain. That is why we conducted national survey and collected 76 case reports. There were six incompletely filled reports, so we analyzed 70 cases.
There were 43 female and 27 male patients. SCS was trialed in an average of 4.7 days (median of 4 days). In most patients, the leads were positioned for the SCS trial with their tips at the level of the T5 vertebral body (26 patients) or T6 vertebral body (15 patients). Four patients failed SCS trial: their average baseline visual analog scale (VAS) pain score was 7 +/- 2.4 cm and did not improve at the conclusion of the trial (6.5 +/- 1.9 cm; P = 0.759). Pain relief exceeded 50% in 66 of 70 patients reported. Among those, VAS pain score before the trial averaged 7.9 +/- 1.8 cm. During the trial VAS pain scores decreased to 2.45 +/- 1.45 cm (P < 0.001). The opioid use decreased from 128 +/- 159 mg of morphine sulfate equivalents a day to 79 +/- 112 mg (P < 0.017). During permanent implantation most of the physicians used two octrode leads and were positioned midline at T5-6 levels. The average patient follow-up was 84 weeks. VAS pain scores before an implant were 8 +/- 1.9 cm, while after the implant 2.49 +/- 1.9 cm. The opioid use before an implant was 158 +/- 160 mg and at the last office visit after the implant 36 +/- 49 mg.
In conclusion, it seems that the SCS for the treatment of the abdominal visceral pain may provide a positive patient long-term experience, significant improvements in pain scores and a decrease in opioid use.
背景、目的和方法:最近有几篇报道表明,脊髓刺激(SCS)可有效抑制慢性腹痛。然而,对于这种疼痛,在患者选择或 SCS 的技术方面尚未达成共识。这就是为什么我们进行了全国性调查,并收集了 76 份病例报告。其中有 6 份报告填写不完整,因此我们分析了 70 份病例。
共有 43 名女性和 27 名男性患者。SCS 的试验平均进行了 4.7 天(中位数为 4 天)。在大多数患者中,SCS 试验的导丝尖端位于 T5 椎体(26 例)或 T6 椎体(15 例)水平。有 4 例患者 SCS 试验失败:他们的平均基线视觉模拟量表(VAS)疼痛评分为 7±2.4cm,试验结束时无改善(6.5±1.9cm;P=0.759)。70 例报告中有 66 例疼痛缓解超过 50%。其中,试验前 VAS 疼痛评分平均为 7.9±1.8cm。试验期间,VAS 疼痛评分降至 2.45±1.45cm(P<0.001)。阿片类药物的使用量从试验前每天 128±159mg 硫酸吗啡当量减少到 79±112mg(P<0.017)。在永久性植入过程中,大多数医生使用两个八极导联,并置于 T5-6 水平的中线位置。平均患者随访时间为 84 周。植入前 VAS 疼痛评分为 8±1.9cm,植入后为 2.49±1.9cm。植入前阿片类药物的使用量为 158±160mg,植入后最后一次就诊时为 36±49mg。
总之,对于治疗腹部内脏疼痛,SCS 似乎可以为患者提供积极的长期体验、显著改善疼痛评分和减少阿片类药物的使用。